TP53 and head and neck squamous cell carcinoma: The success of combination therapies involving TP53, combined with our findings in this study that TP53-Q331* can regulate the expression of ERCC4 and both TP53-Q331* and ERCC4, are associated with poor prognosis of HNSCC, suggesting a potential synergistic effect between TP53 gene therapy with targeted drugs against the NER pathway.